Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis
Aim. To compare the response between the current recommended dosage 13–15 mg/kg/d and 20 mg/kg/d dose of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) patients who do not respond completely to a standard dose of UDCA. Methods. We included 73 patients with poor response and randomi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2021/6691425 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546889866674176 |
|---|---|
| author | Xinyu Xiang Xiaoli Yang Mengyi Shen Chen Huang Yifeng Liu Xiaoli Fan Li Yang |
| author_facet | Xinyu Xiang Xiaoli Yang Mengyi Shen Chen Huang Yifeng Liu Xiaoli Fan Li Yang |
| author_sort | Xinyu Xiang |
| collection | DOAJ |
| description | Aim. To compare the response between the current recommended dosage 13–15 mg/kg/d and 20 mg/kg/d dose of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) patients who do not respond completely to a standard dose of UDCA. Methods. We included 73 patients with poor response and randomized them into two groups to investigate whether increasing the dosage of UDCA was beneficial to nonresponders. Patients assigned to the 13–15 mg/kg/d group continued with standard therapy, and participants in the 18–22 mg/kg/d group switched to the higher dosage (18–22 mg/kg/d), with a follow-up of 12 months for both groups. The primary endpoints were the rate of response at 6 months and drug side effects. Results. According to the Paris 2 criteria, patients receiving 18–22 mg/kg/d UDCA achieved a response rate of 59.4% compared with 36.1% in the standard dosage group (P=0.046) at 6 months, respectively. At 12 months, the high-UDCA-dosage group achieved a response rate of 59.4% compared with 47.2% in the standard dosage group (P=0.295), respectively. Additionally, the risk score predicted by the UK-PBC model was lower in high-dosage UDCA-treated patients than in the standard dosage group (all P<0.05). Side effects include diarrhea, nausea and vomiting, rash, and newly developed high blood pressure, which were mild and tolerated. Conclusions. Patients treated with the high UDCA dosage showed some advantages over those who continued the standard dosage in terms of biochemical remission and disease progression, indicating that standard therapy with UDCA for 6 months and then another 1 year with high UDCA dosage for nonresponders could be a treatment option before second-line therapy is recommended. |
| format | Article |
| id | doaj-art-8cf9a60431b44faab004f099345ed538 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-8cf9a60431b44faab004f099345ed5382025-02-03T06:46:51ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972021-01-01202110.1155/2021/66914256691425Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary CholangitisXinyu Xiang0Xiaoli Yang1Mengyi Shen2Chen Huang3Yifeng Liu4Xiaoli Fan5Li Yang6Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology & Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, ChinaDepartment of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, ChinaAim. To compare the response between the current recommended dosage 13–15 mg/kg/d and 20 mg/kg/d dose of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) patients who do not respond completely to a standard dose of UDCA. Methods. We included 73 patients with poor response and randomized them into two groups to investigate whether increasing the dosage of UDCA was beneficial to nonresponders. Patients assigned to the 13–15 mg/kg/d group continued with standard therapy, and participants in the 18–22 mg/kg/d group switched to the higher dosage (18–22 mg/kg/d), with a follow-up of 12 months for both groups. The primary endpoints were the rate of response at 6 months and drug side effects. Results. According to the Paris 2 criteria, patients receiving 18–22 mg/kg/d UDCA achieved a response rate of 59.4% compared with 36.1% in the standard dosage group (P=0.046) at 6 months, respectively. At 12 months, the high-UDCA-dosage group achieved a response rate of 59.4% compared with 47.2% in the standard dosage group (P=0.295), respectively. Additionally, the risk score predicted by the UK-PBC model was lower in high-dosage UDCA-treated patients than in the standard dosage group (all P<0.05). Side effects include diarrhea, nausea and vomiting, rash, and newly developed high blood pressure, which were mild and tolerated. Conclusions. Patients treated with the high UDCA dosage showed some advantages over those who continued the standard dosage in terms of biochemical remission and disease progression, indicating that standard therapy with UDCA for 6 months and then another 1 year with high UDCA dosage for nonresponders could be a treatment option before second-line therapy is recommended.http://dx.doi.org/10.1155/2021/6691425 |
| spellingShingle | Xinyu Xiang Xiaoli Yang Mengyi Shen Chen Huang Yifeng Liu Xiaoli Fan Li Yang Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis Canadian Journal of Gastroenterology and Hepatology |
| title | Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis |
| title_full | Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis |
| title_fullStr | Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis |
| title_full_unstemmed | Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis |
| title_short | Ursodeoxycholic Acid at 18–22 mg/kg/d Showed a Promising Capacity for Treating Refractory Primary Biliary Cholangitis |
| title_sort | ursodeoxycholic acid at 18 22 mg kg d showed a promising capacity for treating refractory primary biliary cholangitis |
| url | http://dx.doi.org/10.1155/2021/6691425 |
| work_keys_str_mv | AT xinyuxiang ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis AT xiaoliyang ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis AT mengyishen ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis AT chenhuang ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis AT yifengliu ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis AT xiaolifan ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis AT liyang ursodeoxycholicacidat1822mgkgdshowedapromisingcapacityfortreatingrefractoryprimarybiliarycholangitis |